Please assess the completion status of the following clinical trial:

Trial Title: An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Histopathologic confirmation of the following tumor types (please refer to protocol for full details pertaining to eligible tumor types):~  1. Merkel Cell Carcinoma~ 2. Gastric or Gastro-Esophageal junction carcinoma (No longer enrolling this tumor type)~ 3. Nasopharyngeal Carcinoma~ 4. Squamous cell carcinoma (SCC) of the cervix, vagina, or vulva~ 5. Squamous cell carcinoma of the Head and Neck~ 6. Squamous cell carcinoma of the anal canal and penis~ 7. Recurrent/metastatic SCC of the cervix not amenable to curative treatment with surgery and/or radiation therapy who are unsuitable for platinum-based therapy may enroll in the cervical cancer Combination B expansion cohort~* Measurable disease by CT or MRI~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* Patient willing to comply to provide tumor tissue (archival or fresh biopsy specimen)~* Men and women of age 18 or older~Exclusion Criteria:~* Active brain metastases or leptomeningeal metastases~* Patients with active, known or suspected autoimmune disease~* Patients with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications~* Patients with hepatitis~* Patients with HIV~* Pregnant or breastfeeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Neoadjuvant Cohort (Type: EXPERIMENTAL): Nivolumab intravenous infusion as specified~\*\*Not participating: Japan, Korea, and Taiwan
- Metastatic Monotherapy Cohort (Type: EXPERIMENTAL): Nivolumab intravenous infusion as specified
- Nivolumab plus Ipilimumab Cohort (Type: EXPERIMENTAL): Nivolumab intravenous infusion as specified with Ipilimumab intravenous infusion as specified~\*\*Not participating: Belgium, France and Germany~Cohort expansion participating countries: Spain, US, UK, Netherlands, Japan and Mexico~\*\*Not participating in cohort expansion: France, Germany, Korea and Taiwan
- Nivolumab plus Relatlimab Cohort (Type: EXPERIMENTAL): Nivolumab intravenous infusion as specified with Relatlimab intravenous infusion as specified~\*\* Not Participating: Belgium, Germany, France, Japan, Korea, Taiwan, UK, and Netherlands~Enrollment is closed for this cohort
- Nivolumab plus Daratumumab Cohort (Type: EXPERIMENTAL): Nivolumab intravenous infusion as specified with Daratumumab intravenous infusion as specified~\*\*Not Participating: Belgium, Germany, France, Japan, Korea, Taiwan, UK, and Netherlands~Enrollment is closed for this cohort

Based on this trial design, predict the completion outcome and termination type (if applicable).